€8 million capital raising for PVP Laboratoires SEBBIN Funding led by new investors VENTECH, Idinvest Partners and Sigma Gestion
Paris, October 21st 2011 - Bryan, Garnier & Co, the independent pan-European investment bank focusing on growth companies, today announced its Corporate Finance Department successfully arranged a €8 million private placement for PVP Laboratories SEBBIN, one of the largest first round financings in France since the beginning of the year.
Bryan, Garnier & Co acted as exclusive advisor to the company's founders and was sole placement agent. The funding was led by new investors VENTECH (Lead manager), Idinvest Partners and Sigma Gestion.
Acquired in 2010 by Olivier Pérusseau and Diederik Van Goor, PVP Laboratories SEBBIN has over 25 years of experience in the creation, development, production and distribution of a full range of high end implants (implants, expanders, and custom made products) for Aesthetic and Reconstruction surgery. Produced entirely in France, the implants are fabricated at the company's production site in Val d'Oise, and undergo stringent quality control measures before being distributed domestically and internationally in over 50 countries.
This operation will allow PVP Laboratories SEBBIN to strengthen its capital structure, finance its organic growth, and explore external growth opportunities.
"We were very impressed with the turnaround of the company, following its takeover in January 2010. The experienced team at its helm has brought strong organizational, marketing and commercial skills. We have decided to accompany PVP Laboratories SEBBIN's growth, convinced that it will rapidly become a major player in its domain," said Catherine Trividic and Sebastien de Blegiers from Bryan, Garnier & Co.
Olivier Pérusseau, CEO of PVP Laboratories SEBBIN stated, "Thanks to the successful turnaround of the company and the support of our partner surgeons, we have decided to accelerate our growth, notably in international markets. The participation of VENTECH, Idinvest, and Sigma Gestion will be key to our growth plan. Bryan Garnier's experience and understanding of the healthcare sector played a pivotal role in our decision making. Their in depth knowledge allowed us to stick to our targeted timeline in finding solutions to operational issues in addition to leading us to proper investors who would support our growth."
"Being French in the aesthetic and reconstructive surgery market is a clear advantage for PVP Laboratories SEBBIN. The company is seen as a premium actor in this field not only thanks to the quality of its products, but also its rapid execution by its teams," added Mounia Chaoui, General Partner of VENTECH.
List of participants:
- Investors :
- Ventech:
- Mounia Chaoui / General Partner / +33 1 58 19 21 50 / Mounia.chaoui@ventechvc.com
- Idinvest Partners :
- Laurent Dumas-Crouzillac / Partner / +33 1 58 18 56 56 / ldc@idinvest.com
- Sigma Gestion :
- Guillaume Hemmerlé / Directeur de Participations / +33 1 47 03 98 42 / g.hemmerle@sigmagestion.com
- Géraud de Ferrieres / Chargé d'Affaires / +33 1 47 03 98 42 / g.deferrieres@sigmagestion.com
- Ventech:
- Company contacts :
- PVP Laboratoires SEBBIN:
- Olivier Perusseau / Olivier.perusseau@laboratoires-sebbin.fr
- Diederik Van Goor / Diederik.vangoor@laboratoires-sebbin.fr
- PVP Laboratoires SEBBIN:
For more information, please contact:
- Catherine Trividic / Corporate Finance / +33 1 56 68 75 05 / ctrividic@bryangarnier.com
- Sébastien de Blegiers / Corporate Finance / +33 1 56 68 75 74 / sdeblegiers@bryangarnier.com
About PVP Laboratoires Sebbin: www.sebbin.com
For more than 25 years, this French Company, creates, develops, manufactures in France and commercialize high quality implants and expanders throughout the world for the Aesthetic and Reconstruction surgery. In full respect with the company high esthetics, more important than ever, Les Laboratoires Sebbin have become a privileged partner for surgeons to respond to the needs of patients with high qualified products. Les Laboratoires Sebbin are labeled OSEO innovation and also recognized by the Ile de France region for its custom made implants made by 3D technology destinated for thorax deformations.
About Ventech: www.ventech.fr
Ventech is an international Capital Risk fund managing over €400 M of investments in the Health care and New Technology Sector. Since 1998, Ventech invests in ambitious entrepreneurs and his notably invested in amongst others: Meilleur taux (sold to the Caisses d'Epargne after a successful introduction), Musiwave (sold to Openwave), Biovex (sold to Amgen, etc.
About Idinvest Partners: www.idinvest.com
Idinvest is a recognized partner of the Mid Cap private equity market in Europe. With 3 billion euros under management, Idinvest Partners has developed multiple expertises: Capital Risk operations for young and innovative companies; primary and secondary investments or private debt, mezzanine financing and private equity consulting. Created in 1997 under the name AGF Private Equity, branch of Allianz until 2010, the fund was sold to the IDI Group to become independent.
About Sigma Gestion: www.sigmagestion.com
Sigma Gestion is a specialized capital investment fund dedicated to small and mid-sized companies. Member of the ACG Group, Sigma Gestion invests in companies with a strong potential and growth perspective for amounts between 0,3 and 1,5 M€. The investments are in different sectors and company stages, development and divestiture.
About Bryan, Garnier & Co
Bryan, Garnier & Co is an independent investment bank specialising in European TMT, Healthcare and Renewable Energies growth companies. Bryan, Garnier & Co is positioned in three activities: Equity Research & Brokerage, Asset Management and Corporate Finance.
With more than 120 professionals based in London, Paris, New York and Geneva, Bryan, Garnier & Co combines the range of services and the expertise of top-tier investment banks with the level of attention to clients of a boutique.
Through its corporate finance practice, Bryan, Garnier & Co has became a leader in advising European growth companies on strategic finance transactions such as mergers & acquisitions, equity capital market, LBOs and private placement over the last three years.
Bryan, Garnier & Co is authorized and regulated by the Financial Services Authority (FSA) in the United Kingdom, and is member of London Stock Exchange and Euronext, Alternext Listing Sponsor, and is active on all European capital markets.